Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-062468
Filing Date
2022-10-06
Accepted
2022-10-06 16:01:35
Documents
6
Period of Report
2022-10-06

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea166819-6k_nlspharma.htm 6-K 13639
2 NOTICE OF MEETING AND PROXY CARD FOR THE ORDINARY SHAREHOLDERS' MEETING TO BE HE ea166819ex99-1_nlspharma.htm EX-99.1 38791
3 PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES RECEIPT OF STAFF DELISTING DE ea166819ex99-2_nlspharma.htm EX-99.2 10684
4 GRAPHIC ex99-1_001.jpg GRAPHIC 777
5 GRAPHIC ex99-1_002.jpg GRAPHIC 720
6 GRAPHIC ex99-2_001.jpg GRAPHIC 3260
  Complete submission text file 0001213900-22-062468.txt   71084
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 221298159
SIC: 2834 Pharmaceutical Preparations